2,3,4-Trimethoxybenzaldehyde

We are 2,3,4-Trimethoxybenzaldehyde CAS:2103-57-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 2,3,4-Trimethoxybenzaldehyde
CAS.NO: 2103-57-3
Synonyms: 
2,3,4-Trimethoxybenzaldehyde
Benzaldehyde,2,3,4-trimethoxy
2-hydroxy-3-4-dimethoxybenzaldehyde
 
Physical and Chemical Properties:
Density 1.1±0.1 g/cm3
Boiling Point 312.0±37.0 °C at 760 mmHg
Melting Point 38-40 °C(lit.)
Molecular Formula C10H12O4
Molecular Weight 196.200
Flash Point 137.1±26.5 °C
 
Specification:
Appearance: white to pale yellow crystalline powder
Assay: ≥99.0% (GC)
Melting point: 38-41 ° C (2 ° C)
Moisture: ≤0.5%
Single impurity: ≤0.5%
Total impurities: ≤0.5%
Ethanol dissolution test: qualified
 
Packing specification: 25kg/cardboard drum, lined with double plastic bag
Production capacity: 100 tons / year
Application: pharmaceutical intermediates

2,3,4-Trimethoxybenzaldehyde


Related News: As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters.1000994-95-5 Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.4 – ((2-furilmetil) tio) -4-metilpentan-2-ona CAS:64835-96-7 The complete chemical and pharmaceutical industry chain consists of basic chemical raw materials, pharmaceutical intermediates, chemical raw materials and chemical preparations.Methyl 4-Hydroxy-2H-1,2-benzothiazine-3-carboxylate 1,1-Dioxide CAS:35511-14-9 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?

Related Products
Product Name
tert-Butylchlorodiphenylsilane View Details
Furfuryl Mercaptan View Details
cycloheptylmethanol Cas:4448-75-3 View Details
2-Methoxyethanol manufacturer (R,R)-2-amino-1-(4-nitrophenyl)propane-1,3-diol manufacturer diethyl phosphonate manufacturer L-Histidine manufacturer (1S,5R)-2-Oxabicyclo[3.3.0]oct-6-en-3-one manufacturer